RxDoctor Payments DataLook up a doctor →

David Sussman, DO

Urology · Linwood, NJNPI 1407898406

Payments from drug & device makers

$832,564in general payments, 2019–2025

Across 846 payments — averaging $984.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$425K
  • Neotract Inc.$193K
  • AbbVie$90K
  • Urovant Sciences Inc$20K
  • Medtronic$16K
  • Sumitomo Pharma America, Inc.$16K
  • plus $73K from 35 others
$3,499in research payments, 2019–2025

Across 3 payments — averaging $1166.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$3K

What the payments were for

  • Consulting fees$182,85823%
  • Speaking & faculty fees$465,73458%
  • Travel & lodging$121,37715%
  • Food & beverage$31,4564%
  • Education$1270%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$832,564 in reported general payments places this provider in the 95th percentile of 401 urology providers in New Jersey.

See all urology providers in New Jersey

Medicare billing

Part B allowed, 2024
$661,434
Medicare patients
1,290
Services billed
15,568

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron218$220,012
GemtesaVibegron122$123,323
XyostedTestosterone Enanthate31$25,879
Mirabegron ErMirabegron21$14,601
Tamsulosin Hcl739$11,094
Methenamine Hippurate76$9,873
Tolterodine Tartrate ErTolterodine Tartrate121$8,546
Fesoterodine Fumarate ErFesoterodine Fumarate94$7,761
Estradiol49$7,480
ElmironPentosan Polysulfate Sodium12$7,390
Silodosin71$7,284
Tadalafil90$6,029
YuvafemEstradiol41$5,008
Finasteride222$3,915
Trospium Chloride ErTrospium Chloride23$3,723

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$12,587$220,012218 claims
Sumitomo Pharma America, Inc.Gemtesa$15,965$123,323122 claims
Antares Pharma, Inc.Xyosted$14,790$25,87931 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 401 urology providers in New Jersey.

Other urology in Linwood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →